Prof. Dr. Andreas Mackensen

Lehrstuhl für Innere Medizin V

TriCAM (NCT02976558) – a randomized controlled pilot study of complementary medicine in allogeneic stem cell transplantation to improve quality of life (2025) Behzad A, Krause S, Mackensen A, Müller F, Stark A, Völkl S, Rösler W Journal article Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment (2025) Pelzl R, Benintende G, Gsottberger F, Scholz JK, Rübner M, Yao H, Wendland K, et al. Journal article Selective H2-O Tissue Expression Reduces Risk for Graft-versus-Host Disease in an In Vivo Transplantation Model (2025) Zeun J, Bernhardt AL, Neubeck S, Lang V, Korn K, Nagel L, Kunert T, et al. Journal article 3D Tumor microenvironment interaction reveals AP-1 complex regulation and contact-mediated reprogramming of bone marrow stromal cells in chronic lymphocytic leukemia (2025) Lindacher J, Hartebrodt A, Dingfelder J, Lukas P, Würthner L, Völkl S, Blumenthal DB, et al. Journal article One CHiP to rule them all? Mechanistic insight into carfilzomib-induced lung injury with neutrophil extracellular trap formation following cellular immunotherapy (2025) Scholz JK, Stabel L, Schwingen NR, Knopf J, Flatt AS, Bäuerle T, Krause S, et al. Journal article, Medical case study BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells (2025) Müller F, Wirsching A, Hagen M, Völkl S, Tur C, Raimondo MG, Taubmann J, et al. Journal article Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study (2025) Hagen M, Müller F, Wirsching A, Kharboutli S, Spörl S, Düsing C, Krickau T, et al. Journal article Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis Patients (2025) Dingfelder J, Taubmann J, von Heydebrand F, Aigner M, Bergmann C, Knitza J, Park S, et al. Journal article Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT (2025) Flamann C, Shaikh H, Matos C, Kreutz M, Ali H, Kern MA, Büttner-Herold M, et al. Journal article Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma (2025) Müller F, Schwingen NR, Hagen M, Scholz JK, Aigner M, Wirsching A, Taubmann J, et al. Journal article